Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer's disease. - Abbas S; Ferreira PCL; Bellaver B; Povala G; Rohden F; Aguzzoli CS; Zalzale H; Ferrari-Souza JP; Leffa DT; Lussier FZ; Soares C; Bauer-Negrini G; et al. (The journal of prevention of Alzheimer's disease, 2025)